SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes
This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with type 2 diabetes.
GLP-1 Drugs Linked With Chronic Cough
People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a new study found.
Ozempic Brings Back the ‘Mac vs PC’ Ads for the GLP-1 Era
Novo Nordisk is worried about competition and wants to be seen as the cool kid… by using a 20-year-old ad format.
Stevanato (STVN) Declined Due to Anticipation of Soft Quarter Ahead
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ended the fourth quarter on a strong note, with the S&P surging 2.7%, maintaining its steady upward momentum. Investors’ optimism was supported by better-than-expected corporate […]
Novo Nordisk Aims to Set Ozempic Apart From Other GLP-1s in New Ad Campaign
The drugmaker is reprising an Apple campaign with Justin Long and John Hodgman to highlight Ozempic’s FDA-approved uses Drugmaker Novo Nordisk is running ads that play off Apple’s humorous early-aughts “Get a Mac” campaign to try to distinguish Ozempic from other GLP-1 drugs taken for Type 2 …
GLP-1 Drugs May Help Airlines Shed Some Financial Weight
Ozempic isn’t just slimming waistlines—it may be trimming jet fuel bills, too. A new analysis from financial firm Jefferies estimates that if GLP-1 weight loss drugs continue to catch on, the four biggest US airlines—American, Delta, Southwest, and United—could together shave up to $580 million a year…
Vida Health Partners with RxSaveCard to Reduce Rising GLP-1 Costs
SAN FRANCISCO–(BUSINESS WIRE)–Vida Health today announced the launch of Vida Self-Pay (Powered by RxSaveCard) to help employers reduce prescription drug costs.
Doctor’s weight gain warning to anyone taking GLP-1 inhibitors
These medications “don’t magically fix weight loss”, he said
Coca-Cola CEO James Quincey: The U.S. consumer continues to be robust
Coca-Cola chairman and CEO James Quincey joins ‘Squawk Box’ to discuss the state of the consumer, impact of tariffs, impact of GLP-1 drugs on the company, implementation of AI, and more.
Will Trump Win Greenland or Lose Europe? Plus. . .
It’s Tuesday, January 20. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at large. Today: A video report on the activists smuggling Starlink terminals into Iran. Can the sports betting genie be put back in the bottle? Arthur Brooks on how public intellectuals […]